Condition: Healthy Adult Male and Female Volunteers · Sponsor: Centessa Pharmaceuticals (UK) Limited
Characterize the safety, tolerability and pharmacokinetics of ORX489 following single and multiple doses.
This description comes directly from the study's public registry record.
ORX489 Centessa Program Lead ORX489 Centessa Program Lead · 617-468-5770 · ORX489-101study@centessa.com
Celerion Program Lead CA49982 United States, Nebraska [Recruiting]
Always discuss trial participation with your own doctor first.
| Celerion | Lincoln, Nebraska, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07413666